Literature DB >> 9677568

[Radiotherapy of occult neovascularization in senile macular degeneration: initial results of a pilot study].

G Donati1, C J Pournaras, D Soubrane, M Quaranta, G Coscas, G Soubrane.   

Abstract

BACKGROUND: AMD is the leading cause of legal blindness in people aged of more than 50 in industrialized countries. Occult neovascularization accounts for more than 70% of all exsudatives forms of AMD. Radiotherapy has been proposed as a possible treatment for retrofoveal neovascularization. We present the first results of a pilot study actually ongoing at the AMD Center in Creteil. PATIENTS AND METHODS: 44 patients (46 eyes) presenting occult choroidal neovascularization involving the fovea, aged of > 50 years and with a minimal visual acuity of at least 0.1 were included. They received a total dose of 16 Gy in 4 sessions of 4 Gy. All the patients were checked after 3 months.
RESULTS: Visual acuity was globally maintained (> 0.1 in 93% of the eyes). Only one eye suffered a significant loss of vision (> 6 lines) and 11% suffered a moderate loss of vision (> 3 lines). Moreover 67% of eyes still had a near vision of 0.5 or more with reading glasses. On fluorescein angiography 17.5% of the eyes experienced an increase of the size of the occult neovascularization of > 0.5 Disk Area (DA), 76% showed no modification and 6.5% demonstrated a decrease in size of > 0.5 DA.
CONCLUSIONS: As it has been shown that the antimitotic action of radiotherapy is most effective after 3 months, the present results suggest better evolution than natural history. However, as occult choroidal neovascularization is a slow-evolving disease further follow-up is needed to confirm it.

Entities:  

Mesh:

Year:  1998        PMID: 9677568     DOI: 10.1055/s-2008-1034895

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  1 in total

1.  A 5-year follow-up study for distance visual acuity after low dose radiation on subfoveal choroidal neovascularization in age-related macular degeneration.

Authors:  C Valmaggia; G Ries; P Ballinari
Journal:  Doc Ophthalmol       Date:  2001-11       Impact factor: 2.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.